Sripriya Ganesan

Sripriya Ganesan practices at California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California.

Sripriya Ganesan's NPI, 1598874612, was assigned on August 30, 2006. Sripriya Ganesan holds Michigan license 4301087235.

Sripriya Ganesan's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD, at 2333 Buchanan St, San Francisco, CA 94115.

Sripriya Ganesan's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California. Sripriya Ganesan is also affiliated with California Pacific Medical Center Van Ness Campus. The medical group on file is Pacific Inpatient Medical Group. Dmand AI also links Sripriya Ganesan to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Sripriya Ganesan practices, 5 sites in all. Vendor and product names are available with a free account.

Hospitalist is Sripriya Ganesan's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Sripriya Ganesan is licensed in Michigan.

CMS data shows 577 Medicare services from Sripriya Ganesan across 6 procedure codes in 2024, for 194 Medicare patients. Medicare paid $63,948 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 194 Medicare patients who saw Sripriya Ganesan in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 63% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Sripriya Ganesan's median patient age at 69, with 49% women.

In 2024, Sripriya Ganesan wrote 110 Medicare Part D claims for 49 patients. 88% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $122 in total drug cost. In 2021, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Sripriya Ganesan for performance year 2024, reported as part of a group. Sripriya Ganesan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Sripriya Ganesan from 1 drug or device company in 2017. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $30.